Targeting proteasomal pathways by dietary curcumin for cancer prevention and treatment

Current Medicinal Chemistry

Volumn 21, Issue 14, 2014, Pages 1583-1594

  Hasima, Noor ^a,b   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Cancer; Cell death; Curcumin; Degradation; Inflammatory protein; Prevention; Proteasome; Transcription factor; Treatment; Ubiquitination

Indexed keywords

CARBON; CHYMOTRYPSIN; COP9 SIGNALOSOME; CURCUMIN; CYCLIN D1; CYCLIN E; CYCLOOXYGENASE 2; DNA TOPOISOMERASE (ATP HYDROLYSING); E1A ASSOCIATED P300 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HISTONE DEACETYLASE 2; HYDROXYL GROUP; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; KETONE; PROTEASOME; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; STAT3 PROTEIN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; THREONINE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP; UBIQUITIN; VASCULOTROPIN; PROTEINASE INHIBITOR; TRANSCRIPTION FACTOR;

AMINO TERMINAL SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER PREVENTION; CANCER THERAPY; CONCENTRATION RESPONSE; CURCUMA LONGA; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; NONHUMAN; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEOPLASM;

ANIMALS; CURCUMIN; HUMANS; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84899818564     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113206660135     Document Type: Review

References (96)

1. Ruggeri, B.; Miknyoczki, S.; Dorsey, B.; Hui, A.M. The development and pharmacology of proteasome inhibitors for the management and treatment of cancer. Adv. Pharmacol., 2009, 57, 91-135.
2. Coux, O.; Tanaka, K.; Goldberg, A.L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem., 1996, 65, 801-847.
3. Silva, G.M.; Netto, L.E.; Simoes, V.; Santos, L.F.; Gozzo, F.C.; Demasi, M.A.; Oliveira, C.L.; Bicev, R.N.; Klitzke, C.F.; Sogayar, M.C.; Demasi, M. Redox Control of 20S Proteasome Gating. Antioxid Redox Signal, 2012, 16(11), 1183-1194.
4. Chauhan, D.; Hideshima, T.; Anderson, K.C. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 465-476.
5. Adams, J.; Behnke, M.; Chen, S.; Cruickshank, A.A.; Dick, L.R.; Grenier, L.; Klunder, J.M.; Ma, Y.T.; Plamondon, L.; Stein, R.L., Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett., 1998, 8(4), 333-338.
6. Adams, J.; Palombella, V.J.; Sausville, E.A.; Johnson, J.; Destree, A.; Lazarus, D.D.; Maas, J.; Pien, C.S.; Prakash, S.; Elliott, P.J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res., 1999, 59(11), 2615-2622.
7. Orlowski, R.Z. Bortezomib and its role in the management of patients with multiple myeloma. Expert Rev. Anticancer Ther., 2004, 4(2), 171-179.
8. Kuhn, D.J.; Chen, Q.; Voorhees, P.M.; Strader, J.S.; Shenk, K.D.; Sun, C.M.; Demo, S.D.; Bennett, M.K.; van Leeuwen, F.W.; Chanan-Khan, A.A.; Orlowski, R.Z. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitinproteasome pathway, against preclinical models of multiple myeloma. Blood, 2007, 110(9), 3281-3290.
9. Ahn, K.S.; Sethi, G.; Chao, T.H.; Neuteboom, S.T.; Chaturvedi, M.M.; Palladino, M.A.; Younes, A.; Aggarwal, B.B. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products. Blood, 2007, 110(7), 2286-2295.
10. Meng, L.; Mohan, R.; Kwok, B.H.; Elofsson, M.; Sin, N.; Crews, C.M. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. U. S. A., 1999, 96(18), 10403-10408.
11. Schneekloth, J.S., Jr.; Crews, C.M. Natural product inhibitors of the ubiquitin-proteasome pathway. Curr. Drug Targets, 2011, 12(11), 1581-1594.
12. Gu, W.; Silverman, R.B. Stereospecific total syntheses of proteasome inhibitors omuralide and lactacystin. J. Org. Chem., 2011, 76(20), 8287-8293.
13. Rock, K.L.; Gramm, C.; Rothstein, L.; Clark, K.; Stein, R.; Dick, L.; Hwang, D.; Goldberg, A.L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell, 1994, 78(5), 761-771.
14. Zhu, K.; Dunner, K., Jr.; McConkey, D.J. Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene, 2010, 29(3), 451-462.
15. Levine, B.; Kroemer, G. Autophagy in the pathogenesis of disease. Cell, 2008, 132(1), 27-42.
16. Hideshima, T.; Mitsiades, C.; Akiyama, M.; Hayashi, T.; Chauhan, D.; Richardson, P.; Schlossman, R.; Podar, K.; Munshi, N.C.; Mitsiades, N.; Anderson, K.C. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 2003, 101(4), 1530-1534.
17. Chauhan, D.; Bianchi, G.; Anderson, K.C. Targeting the UPS as therapy in multiple myeloma. BMC Biochem., 2008, 9 Suppl 1, S1.
18. Zhao, M.; Vuori, K. The docking protein p130Cas regulates cell sensitivity to proteasome inhibition. BMC Biol., 2011, 9, 73.
19. Milacic, V.; Banerjee, S.; Landis-Piwowar, K.R.; Sarkar, F.H.; Majumdar, A.P.; Dou, Q.P. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res., 2008, 68(18), 7283-7292.
20. Henke, W.; Ferrell, K.; Bech-Otschir, D.; Seeger, M.; Schade, R.; Jungblut, P.; Naumann, M.; Dubiel, W. Comparison of human COP9 signalsome and 26S proteasome lid'. Mol. Biol. Rep., 1999, 26(1-2), 29-34.
21. Uhle, S.; Medalia, O.; Waldron, R.; Dumdey, R.; Henklein, P.; Bech-Otschir, D.; Huang, X.; Berse, M.; Sperling, J.; Schade, R.; Dubiel, W. Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. EMBO. J., 2003, 22(6), 1302-1312.
22. Seeger, M.; Kraft, R.; Ferrell, K.; Bech-Otschir, D.; Dumdey, R.; Schade, R.; Gordon, C.; Naumann, M.; Dubiel, W. A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. FASEB. J., 1998, 12(6), 469-478.
23. Bech-Otschir, D.; Seeger, M.; Dubiel, W. The COP9 signalosome: at the interface between signal transduction and ubiquitin-dependent proteolysis. J. Cell Sci., 2002, 115(Pt 3), 467-473.
24. Berse, M.; Bounpheng, M.; Huang, X.; Christy, B.; Pollmann, C.; Dubiel, W. Ubiquitin-dependent degradation of Id1 and Id3 is mediated by the COP9 signalosome. J. Mol. Biol., 2004, 343(2), 361-370.
25. Mullally, J.E.; Fitzpatrick, F.A. Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death. Mol. Pharmacol., 2002, 62(2), 351-358.
26. Gupta, S.C.; Prasad, S.; Kim, J.H.; Patchva, S.; Webb, L.J.; Priyadarsini, I.K.; Aggarwal, B.B. Multitargeting by curcumin as revealed by molecular interaction studies. Nat. Prod. Rep., 2011, 28, (12), 1937-1955.
27. Ali, R.E.; Rattan, S.I. Curcumin's biphasic hormetic response on proteasome activity and heat-shock protein synthesis in human keratinocytes. Ann. N. Y. Acad. Sci., 2006, 1067, 394-399.
28. Bhaumik, S.; Anjum, R.; Rangaraj, N.; Pardhasaradhi, B.V.; Khar, A. Curcumin mediated apoptosis in AK-5 tumor cells involves the production of reactive oxygen intermediates. FEBS. Lett., 1999, 456(2), 311-314.
29. Woo, J.H.; Kim, Y.H.; Choi, Y.J.; Kim, D.G.; Lee, K.S.; Bae, J.H.; Min, D.S.; Chang, J.S.; Jeong, Y.J.; Lee, Y.H.; Park, J.W.; Kwon, T.K. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis, 2003, 24(7), 1199-1208.
30. Sandur, S.K.; Ichikawa, H.; Pandey, M.K.; Kunnumakkara, A.B.; Sung, B.; Sethi, G.; Aggarwal, B.B. Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radic. Biol. Med., 2007, 43(4), 568-580.
31. Okada, K.; Wangpoengtrakul, C.; Osawa, T.; Toyokuni, S.; Tanaka, K.; Uchida, K. 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J. Biol. Chem., 1999, 274(34), 23787-23793.
32. Ding, Q.; Keller, J.N. Proteasome inhibition in oxidative stress neurotoxicity: implications for heat shock proteins. J. Neurochem., 2001, 77(4), 1010-1017.
33. Reddy, A.C.; Lokesh, B.R. Effect of dietary turmeric (Curcuma longa) on iron-induced lipid peroxidation in the rat liver. Food Chem. Toxicol., 1994, 32(3), 279-283.
34. Ruby, A.J.; Kuttan, G.; Babu, K.D.; Rajasekharan, K.N.; Kuttan, R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett., 1995, 94(1), 79-83.
35. Singh, S.; Aggarwal, B.B. Activation of transcription factor NFkappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J. Biol. Chem., 1995, 270(42), 24995-25000.
36. Bech-Otschir, D.; Kraft, R.; Huang, X.; Henklein, P.; Kapelari, B.; Pollmann, C.; Dubiel, W. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO. J., 2001, 20(7), 1630-1639.
37. Jana, N.R.; Dikshit, P.; Goswami, A.; Nukina, N., Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J. Biol. Chem., 2004, 279(12), 11680-11685.
38. Yun, J.; Tomida, A.; Andoh, T.; Tsuruo, T. Interaction between glucose-regulated destruction domain of DNA topoisomerase IIalpha and MPN domain of Jab1/CSN5. J. Biol. Chem., 2004, 279(30), 31296-31303.
39. Wyke, S.M.; Russell, S.T.; Tisdale, M.J. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br. J. Cancer, 2004, 91(9), 1742-1750.
40. Callige, M.; Kieffer, I.; Richard-Foy, H. CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptor {alpha} by the proteasome. Mol. Cell. Biol., 2005, 25(11), 4349-4358.
41. Franck, N.; Le Seyec, J.; Guguen-Guillouzo, C.; Erdtmann, L. Hepatitis C virus NS2 protein is phosphorylated by the protein kinase CK2 and targeted for degradation to the proteasome. J. Virol., 2005, 79(5), 2700-2708.
42. Dikshit, P.; Goswami, A.; Mishra, A.; Chatterjee, M.; Jana, N.R. Curcumin induces stress response, neurite outgrowth and prevent NF-kappaB activation by inhibiting the proteasome function. Neurotox. Res., 2006, 9(1), 29-37.
43. Zhang, H.G.; Kim, H.; Liu, C.; Yu, S.; Wang, J.; Grizzle, W.E.; Kimberly, R.P.; Barnes, S. Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicity. Biochim. Biophys. Acta, 2007, 1773(7), 1116-1123.
44. Si, X.; Wang, Y.; Wong, J.; Zhang, J.; McManus, B.M.; Luo, H. Dysregulation of the ubiquitin-proteasome system by curcumin suppresses coxsackievirus B3 replication. J. Virol., 2007, 81(7), 3142-3150.
45. Poylin, V.; Fareed, M.U.; O'Neal, P.; Alamdari, N.; Reilly, N.; Menconi, M.; Hasselgren, P.O. The NF-kappaB inhibitor curcumin blocks sepsis-induced muscle proteolysis. Mediators Inflamm., 2008, 2008, 317851.
46. Meja, K.K.; Rajendrasozhan, S.; Adenuga, D.; Biswas, S.K.; Sundar, I.K.; Spooner, G.; Marwick, J.A.; Chakravarty, P.; Fletcher, D.; Whittaker, P.; Megson, I.L.; Kirkham, P.A.; Rahman, I. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am. J. Respir. Cell Mol. Biol., 2008, 39(3), 312-323.
47. Dutta, K.; Ghosh, D.; Basu, A. Curcumin protects neuronal cells from Japanese encephalitis virus-mediated cell death and also inhibits infective viral particle formation by dysregulation of ubiquitin-proteasome system. J. Neuroimmune Pharmacol., 2009, 4(3), 328-337.
48. Siddiqui, R.A.; Hassan, S.; Harvey, K.A.; Rasool, T.; Das, T.; Mukerji, P.; DeMichele, S. Attenuation of proteolysis and muscle wasting by curcumin c3 complex in MAC16 colon tumourbearing mice. Br. J. Nutr., 2009, 102(7), 967-975.
49. O'Sullivan-Coyne, G.; O'Sullivan, G.C.; O'Donovan, T.R.; Piwocka, K.; McKenna, S.L. Curcumin induces apoptosisindependent death in oesophageal cancer cells. Br. J. Cancer, 2009, 101(9), 1585-1595.
50. Yoon, M.J.; Kim, E.H.; Lim, J.H.; Kwon, T.K.; Choi, K.S. Superoxide anion and proteasomal dysfunction contribute to curcumin-induced paraptosis of malignant breast cancer cells. Free Radic. Biol. Med., 2010, 48(5), 713-726.
51. Song, K.; Peng, S.; Sun, Z.; Li, H.; Yang, R. Curcumin suppresses TGF-beta signaling by inhibition of TGIF degradation in scleroderma fibroblasts. Biochem. Biophys. Res. Commun., 2011, 411(4), 821-825.
52. Khan, S.; Heikkila, J.J. Curcumin-induced inhibition of proteasomal activity, enhanced HSP accumulation and the acquisition of thermotolerance in Xenopus laevis A6 cells. Comp. Biochem. Physiol. A. Mol. Integr. Physiol., 2011, 158(4), 566-576.
53. Vazeille, E.; Slimani, L.; Claustre, A.; Magne, H.; Labas, R.; Bechet, D.; Taillandier, D.; Dardevet, D.; Astruc, T.; Attaix, D.; Combaret, L. Curcumin treatment prevents increased proteasome and apoptosome activities in rat skeletal muscle during reloading and improves subsequent recovery. J. Nutr. Biochem., 2012, 23(3), 245-251.
54. Pollmann, C.; Huang, X.; Mall, J.; Bech-Otschir, D.; Naumann, M.; Dubiel, W. The constitutive photomorphogenesis 9 signalosome directs vascular endothelial growth factor production in tumor cells. Cancer Res., 2001, 61(23), 8416-8421.
55. Mukhopadhyay, A.; Banerjee, S.; Stafford, L.J.; Xia, C.; Liu, M.; Aggarwal, B.B. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene, 2002, 21(57), 8852-8861.
56. Balasubramanian, S.; Eckert, R.L. Green tea polyphenol and curcumin inversely regulate human involucrin promoter activity via opposing effects on CCAAT/enhancer-binding protein function. J. Biol. Chem., 2004, 279(23), 24007-24014.
57. Choi, H.; Chun, Y.S.; Kim, S.W.; Kim, M.S.; Park, J.W. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol. Pharmacol., 2006, 70(5), 1664-1671.
58. Marcu, M.G.; Jung, Y.J.; Lee, S.; Chung, E.J.; Lee, M.J.; Trepel, J.; Neckers, L. Curcumin is an inhibitor of p300 histone acetylatransferase. Med. Chem., 2006, 2(2), 169-174.
59. Aggarwal, B.B.; Banerjee, S.; Bharadwaj, U.; Sung, B.; Shishodia, S.; Sethi, G. Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem. Pharmacol., 2007, 73(7), 1024-1032.
60. Balasubramanian, S.; Eckert, R.L. Curcumin suppresses AP1 transcription factor-dependent differentiation and activates apoptosis in human epidermal keratinocytes. J. Biol. Chem., 2007, 282(9), 6707-6715.
61. Srivastava, R.K.; Chen, Q.; Siddiqui, I.; Sarva, K.; Shankar, S. Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1). Cell Cycle, 2007, 6(23), 2953-2961.
62. Neuss, H.; Huang, X.; Hetfeld, B.K.; Deva, R.; Henklein, P.; Nigam, S.; Mall, J.W.; Schwenk, W.; Dubiel, W. The ubiquitinand proteasome-dependent degradation of COX-2 is regulated by the COP9 signalosome and differentially influenced by coxibs. J. Mol. Med. (Berl.), 2007, 85(9), 961-970.
63. Chadalapaka, G.; Jutooru, I.; Chintharlapalli, S.; Papineni, S.; Smith, R., 3rd; Li, X.; Safe, S. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res., 2008, 68(13), 5345-5354.
64. Chanvorachote, P.; Pongrakhananon, V.; Wannachaiyasit, S.; Luanpitpong, S.; Rojanasakul, Y.; Nimmannit, U. Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation. Cancer Invest., 2009, 27(6), 624-635.
65. Lee, J.H.; Chung, I.K. Curcumin inhibits nuclear localization of telomerase by dissociating the Hsp90 co-chaperone p23 from hTERT. Cancer Lett., 2010, 290(1), 76-86.
66. Hsin, I.L.; Sheu, G.T.; Chen, H.H.; Chiu, L.Y.; Wang, H.D.; Chan, H.W.; Hsu, C.P.; Ko, J.L. N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells. Mutat. Res., 2010, 688(1-2), 72-77.
67. Ben, P.; Liu, J.; Lu, C.; Xu, Y.; Xin, Y.; Fu, J.; Huang, H.; Zhang, Z.; Gao, Y.; Luo, L.; Yin, Z. Curcumin promotes degradation of inducible nitric oxide synthase and suppresses its enzyme activity in RAW 264.7 cells. Int. Immunopharmacol., 2011, 11(2), 179-186.
68. Fossey, S.L.; Bear, M.D.; Lin, J.; Li, C.; Schwartz, E.B.; Li, P.K.; Fuchs, J.R.; Fenger, J.; Kisseberth, W.C.; London, C.A. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. BMC Cancer, 2011, 11, 112.
69. Di Zanni, E.; Bachetti, T.; Parodi, S.; Bocca, P.; Prigione, I.; Di Lascio, S.; Fornasari, D.; Ravazzolo, R.; Ceccherini, I. In vitro drug treatments reduce the deleterious effects of aggregates containing polyAla expanded PHOX2B proteins. Neurobiol. Dis., 2012, 45(1), 508-518.
70. Kumar, A.; Dhawan, S.; Hardegen, N.J.; Aggarwal, B.B. Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem. Pharmacol., 1998, 55(6), 775-783.
71. Jobin, C.; Bradham, C.A.; Russo, M.P.; Juma, B.; Narula, A.S.; Brenner, D.A.; Sartor, R.B. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J. Immunol., 1999, 163(6), 3474-3483.
72. Aggarwal, S.; Ichikawa, H.; Takada, Y.; Sandur, S.K.; Shishodia, S.; Aggarwal, B.B. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol. Pharmacol., 2006, 69(1), 195-206.
73. Huang, T.S.; Lee, S.C.; Lin, J.K. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc. Natl. Acad. Sci. U. S. A., 1991, 88(12), 5292-5296.
74. Bharti, A.C.; Donato, N.; Aggarwal, B.B. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol., 2003, 171(7), 3863-3871.
75. Jee, S.H.; Shen, S.C.; Tseng, C.R.; Chiu, H.C.; Kuo, M.L. Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. J. Invest. Dermatol., 1998, 111(4), 656-661.
76. Tsvetkov, P.; Asher, G.; Reiss, V.; Shaul, Y.; Sachs, L.; Lotem, J. Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc. Natl. Acad. Sci. U. S. A., 2005, 102(15), 5535-5540.
77. Zhang, X.C.; Chen, J.; Su, C.H.; Yang, H.Y.; Lee, M.H. Roles for CSN5 in control of p53/MDM2 activities. J. Cell. Biochem., 2008, 103(4), 1219-1230.
78. Wang, X.Z.; Kuroda, M.; Sok, J.; Batchvarova, N.; Kimmel, R.; Chung, P.; Zinszner, H.; Ron, D. Identification of novel stressinduced genes downstream of chop. EMBO. J., 1998, 17(13), 3619-3630.
79. Zhong, H.; De Marzo, A.M.; Laughner, E.; Lim, M.; Hilton, D.A.; Zagzag, D.; Buechler, P.; Isaacs, W.B.; Semenza, G.L.; Simons, J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res., 1999, 59(22), 5830-5835.
80. Ryan, H.E.; Poloni, M.; McNulty, W.; Elson, D.; Gassmann, M.; Arbeit, J.M.; Johnson, R.S. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res., 2000, 60(15), 4010-4015.
81. Higgins, K.J.; Abdelrahim, M.; Liu, S.; Yoon, K.; Safe, S. Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem. Biophys. Res. Commun., 2006, 345(1), 292-301.
82. Abdelrahim, M.; Baker, C.H.; Abbruzzese, J.L.; Sheikh-Hamad, D.; Liu, S.; Cho, S.D.; Yoon, K.; Safe, S. Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res., 2007, 67(7), 3286-3294.
83. Chintharlapalli, S.; Papineni, S.; Ramaiah, S.K.; Safe, S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res., 2007, 67(6), 2816-2823.
84. Hong, R.L.; Spohn, W.H.; Hung, M.C. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin. Cancer Res., 1999, 5(7), 1884-1891.
85. Sperandio, S.; de Belle, I.; Bredesen, D.E. An alternative, nonapoptotic form of programmed cell death. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(26), 14376-14381.
86. Sperandio, S.; Poksay, K.; de Belle, I.; Lafuente, M.J.; Liu, B.; Nasir, J.; Bredesen, D.E., Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix. Cell Death Differ., 2004, 11(10), 1066-1075
87. Valamanesh, F.; Torriglia, A.; Savoldelli, M.; Gandolphe, C.; Jeanny, J.C.; BenEzra, D.; Behar-Cohen, F. Glucocorticoids induce retinal toxicity through mechanisms mainly associated with paraptosis. Mol. Vis., 2007, 13, 1746-1757.
88. Takakura, M.; Kyo, S.; Kanaya, T.; Hirano, H.; Takeda, J.; Yutsudo, M.; Inoue, M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res., 1999, 59(3), 551-557.
89. Hsu, C.P.; Hsu, N.Y.; Lee, L.W.; Ko, J.L. Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter-effect on telomerase expression and telomere length maintenance in non-small cell lung cancer. Eur. J. Cancer, 2006, 42(10), 1466-1474.
90. Kyo, S.; Takakura, M.; Fujiwara, T.; Inoue, M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci., 2008, 99(8), 1528-1538.
91. Cho, J.W.; Lee, K.S.; Kim, C.W. Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int. J. Mol. Med., 2007, 19(3), 469-474.
92. Abusnina, A.; Keravis, T.; Yougbare, I.; Bronner, C.; Lugnier, C. Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. Mol. Nutr. Food Res., 2011, 55(11), 1677-1689.
93. Pongrakhananon, V.; Nimmannit, U.; Luanpitpong, S.; Rojanasakul, Y.; Chanvorachote, P. Curcumin sensitizes non-small cell lung cancer cell anoikis through reactive oxygen speciesmediated Bcl-2 downregulation. Apoptosis, 2010, 15(5), 574-585.
94. Debes, J.D.; Schmidt, L.J.; Huang, H.; Tindall, D.J., p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res., 2002, 62(20), 5632-5636
95. Bandyopadhyay, D.; Okan, N.A.; Bales, E.; Nascimento, L.; Cole, P.A.; Medrano, E.E. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res., 2002, 62(21), 6231-6239.
96. Sung, B.; Kunnumakkara, A.B.; Sethi, G.; Anand, P.; Guha, S.; Aggarwal, B.B. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol. Cancer Ther., 2009, 8(4), 959-970.